Inmune Bio INMB Income Statement (2017-2026)

NASDAQ INMB
$1.10 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Inmune Bio Quarterly Income Statement

Periods 36 quarters
Latest Sep 2026

Inmune Bio reported net income of -$4.74M for the quarter ended Sep 2026. This income statement covers 36 quarters of results from Dec 2017 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.16M0.16M0.02M0.10M0.10M0.04M0.05M0.04M0.03M0.01M0.05M
Operating items
Research & DevelopmentR&D
7.07M4.31M4.19M5.16M3.41M4.13M4.15M5.99M6.01M8.69M7.05M10.07M7.35M7.64M5.80M4.89M2.33M3.64M-0.80M3.16M
Selling, General & AdministrativeSG&A
2.13M2.33M2.22M2.38M2.33M2.33M2.31M2.59M2.40M2.34M2.81M2.22M2.11M2.32M2.25M2.55M3.15M2.17M2.28M1.85M
Other Operating ExpensesOther Opex
-1.73M-0.43M0.45M0.28M0.19M-0.11M-0.09M0.04M-0.51M-0.01M0.12M16.51M
Operating ExpensesOpex
9.19M6.64M6.40M7.54M5.74M6.46M6.46M8.57M8.41M11.03M9.87M12.29M9.47M9.96M24.57M7.43M5.47M5.81M1.48M5.01M
Operating IncomeOp. Inc
-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.91M-24.57M-7.43M-5.47M-5.81M-1.48M-5.01M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
-0.09M-0.04M-0.03M-0.01M0.12M0.19M0.25M0.17M
Non Operating IncomeNon Op. Inc.
-0.64M-0.43M-0.04M-0.03M0.12M0.19M0.25M0.17M0.11M0.96M0.21M0.41M0.20M0.29M
Net income details
EBIT
-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.91M-24.57M-7.43M-5.47M-5.81M-1.48M-5.01M
EBT
-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.91M-24.57M-7.43M-5.47M-5.81M-1.48M-5.01M
Income After Tax
-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.91M-24.57M-7.43M-5.47M-5.81M-1.48M-5.01M
Income from Continuing OperationsIncome (Continuing)
-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.91M-24.57M-7.43M-5.47M-5.81M-1.48M-5.01M
Consolidated Net IncomeConsol Net Inc.
-9.55M-6.90M-7.60M-8.17M-5.39M-6.55M-6.51M-8.59M-8.47M-10.90M-9.79M-12.42M-8.76M-9.77M-24.61M-6.47M-5.24M-5.40M-1.37M-4.74M
Income towards Parent CompanyParent Net Inc
-9.67M-6.90M-6.84M-7.73M-5.83M-6.54M-6.50M-8.56M-8.41M-11.03M-9.75M-12.09M-9.24M-9.74M-24.46M-6.47M-5.26M-5.41M-1.27M-4.72M
Net Income towards Common StockholdersNet Income
-9.67M-6.90M-6.84M-7.73M-5.83M-6.54M-6.50M-8.56M-8.41M-11.03M-9.75M-12.09M-9.24M-9.74M-24.46M-6.47M-5.26M-5.41M-1.27M-4.72M
Additional items
EPS (Basic)
-0.60-0.39-0.38-0.43-0.33-0.36-0.36-0.48-0.47-0.61-0.50-0.60-0.46-0.43-1.05-0.24-0.21-0.20-0.05-0.17
EPS (Diluted)
-0.60-0.39-0.38-0.43-0.33-0.36-0.36-0.48-0.47-0.61-0.50-0.60-0.46-0.43-1.05-0.24-0.21-0.20-0.05-0.17
Shares Outstanding
16.13M17.87M17.95M17.95M17.93M17.95M17.95M18.01M17.98M18.03M19.31M20.19M19.94M22.50M23.30M26.59M24.76M26.59M26.72M27.81M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
16.13M17.87M17.95M17.95M17.93M17.95M17.95M18.01M17.98M18.03M19.31M20.19M19.94M22.50M23.30M26.59M24.76M26.59M26.72M27.81M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
17.84M17.95M17.95M17.95M17.95M17.95M17.95M17.95M17.95M17.95M19.71M22.17M22.28M22.93M26.59M26.59M26.59M26.59M27.65M27.92M
EBITDA
-5.42M-5.76M-1.38M-4.91M

Inmune Bio Income Statement API

Pull Inmune Bio's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=INMB&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY